Gene Marcial

Gene Marcial

InvestorPlace Contributor

Gene Marcial is a long-time observer of the investing world, having worked for The Wall Street Journal and BusinessWeek, where he wrote the closely followed “Inside Wall Street” column for 28 years. He now writes for MSN Money and contributes to Forbes. His most recent book is “Seven Commandments of Stock Investing,” published by FT Press.

Recent Articles

Xerox: Making Progress on the Comeback Path

By Gene Marcial, InvestorPlace Contributor

Its transition to a digital world is steadily taking shape. Wall Street isn't paying much attention, but XRX could be a long-term turnaround bet.

Cue the Biotech M&A Attack!

By Gene Marcial, InvestorPlace Contributor

A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.

ConocoPhillips’ Happy Divorce

By Gene Marcial, InvestorPlace Contributor

The spin-off of the refining operations is good news for investors.

Here Comes a Bidding War for Amylin

By Gene Marcial, InvestorPlace Contributor

Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.

What the Bears Miss About Las Vegas Sands

By Gene Marcial, InvestorPlace Contributor

Investors under-appreciate the growth opportunities in Macau and Singapore.

Pony Up for American Express

By Gene Marcial, InvestorPlace Contributor

Stress test winner American Express has it all: Solid financial footing, growing revenues and profits, a newly raised dividend -- and an alluring valuation.

This Small-Cap Telecom Deserves Your Attention

By Gene Marcial, InvestorPlace Contributor

Cincinnati Bell is mulling a spin-off that would unlock a lot of value. It's attracting some big-money interest -- and you should be watching it, too.

Why Starbucks Is Still Steaming Hot

By Gene Marcial, InvestorPlace Contributor

Innovative products, improved customer service and new efforts in Europe and India should keep the java giant growing for years to come.

Mattel Is Serious Fun for Investors

By Gene Marcial, InvestorPlace Contributor

The No. 1 toymaker's stock keeps rolling -- and its dividend keeps rising -- as it continues to keep the hit toys coming in markets around the world.

Why Illumina’s Future Remains Bright

By Gene Marcial, InvestorPlace Contributor

Rejection of Roche's takeover bid has cooled ILMN shares, but many expect Roche to step up its advances. If not, Illumina still has great growth prospects.

Load More